[1]张永胜,唐武兵.大剂量利可君对盆腔肿瘤调强适形放疗所致骨髓抑制的疗效[J].医学信息,2021,34(16):131-133.[doi:10.3969/j.issn.1006-1959.2021.16.036]
　ZHANG Yong-sheng,TANG Wu-bing.Efficacy of High-dose Leucogen on Bone Marrow Suppression Induced by Intensity-modulated Conformal Radiotherapy for Pelvic Tumors[J].Medical Information,2021,34(16):131-133.[doi:10.3969/j.issn.1006-1959.2021.16.036]
点击复制

大剂量利可君对盆腔肿瘤调强适形放疗所致骨髓抑制的疗效()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年16期
页码:
131-133
栏目:
临床研究
出版日期:
2021-08-15

文章信息/Info

Title:
Efficacy of High-dose Leucogen on Bone Marrow Suppression Induced by Intensity-modulated Conformal Radiotherapy for Pelvic Tumors
文章编号:
1006-1959（2021）16-0131-03
作者:
张永胜; 唐武兵
（1.香港大学深圳医院临床肿瘤中心，广东 深圳 518000； 2.南方医科大学附属南海医院肿瘤一科，广东 佛山 528200； 3.南方医科大学第二临床医学院，广东 广州 510000）
Author(s):
ZHANG Yong-sheng; TANG Wu-bing
(1.Clinical Oncology Center,the University of Hong Kong-Shenzhen Hospital,Shenzhen 518000,Guangdong,China; 2.Department of Oncology,Nanhai Hospital,Southern Medical University,Foshan 528200, Guangdong,China; 3.The Second Clinical School of Southern Medica
关键词:
利可君; 盆腔恶性肿瘤; 调强适形放疗; 骨髓抑制
Keywords:
Leucogen; Pelvic malignant tumor; Intensity-modulated conformal radiotherapy; Bone marrow suppression
分类号:
R730.55
DOI:
10.3969/j.issn.1006-1959.2021.16.036
文献标志码:
A
摘要:
目的 探讨利可君对恶性肿瘤盆腔放疗所致骨髓抑制的临床疗效。方法 选取2017年1月1日~2020年12月20日在南方医科大学附属南海医院收治的盆腔肿瘤术后放疗的患者96例，随机分为观察组及对照组，每组48例，对照组予以调强适形放疗，观察组则在放疗前1周开始服用大剂量利可君预防性治疗，比较两组治疗完成情况、骨髓抑制情况、白细胞及血小板变化情况及不良反应发生情况。结果 两组放疗完成率均为100.00%；观察组骨髓抑制总发生率低于对照组，差异有统计学意义（P＜0.05）；放疗后两组白细胞与血小板计数均下降，且对照组低于观察组，差异有统计学意义（P＜0.05）；两组均未见恶心呕吐，腹泻腹痛等利可君药物相关的不良反应，肝肾功能均正常。结论 盆腔调强适形放疗所致骨髓抑制反应发生率较高，大剂量利可君在防治盆腔恶性肿瘤患者调强适形放疗所致骨髓抑制方面具有较好的效果，且无明显不良反应，安全可靠。
Abstract:
Objective To investigate the clinical effect of Leucogen on bone marrow suppression caused by pelvic radiotherapy of malignant tumors.Methods A total of 96 patients undergoing postoperative radiotherapy for pelvic tumors who were admitted to Nanhai Hospital of Southern Medical University from January 1, 2017 to December 20, 2020 were randomly divided into observation group and control group, with 48 cases in each group.The control group received intensity-modulated conformal radiotherapy, while the observation group began to take prophylactic treatment with high-dose Leucogen 1 week before radiotherapy.The completion of treatment, bone marrow suppression, white blood cell and platelet changes and adverse reactions were compared between the two groups.Results The completion rate of radiotherapy in both groups was 100.00%; the total incidence of bone marrow suppression in the observation group was lower than that in the control group,the difference was statistically significant(P<0.05);After radiotherapy, the white blood cell and platelet counts of the two groups decreased, and the control group was lower than the observation group,the difference was statistically significant (P<0.05);There were no adverse reactions related to Leucogen such as nausea, vomiting, diarrhea, abdominal pain, etc., and liver and kidney functions were normal.Conclusion The incidence of bone marrow suppression caused by pelvic intensity-modulated conformal radiotherapy is higher.High-dose Leucogen has a good effect in the prevention and treatment of bone marrow suppression caused by intensity modulated radiotherapy in patients with pelvic malignant tumors, and it has no obvious adverse reactions and is safe and reliable.

参考文献/References:

[1]叶奕菁,钟宗良,欧阳玉秀,等.直肠癌术后盆腔放疗方式及剂量对骨髓功能的影响[J].中国肿瘤外科杂志,2018,10(2):92-95,101. [2]卢盼,孙绍星,邱惠,等.宫颈癌调强放疗中骨盆剂量体积参数与急性骨髓抑制的关系[J].医学新知杂志,2019,29(2):138-141,144. [3]Dracham CB,Mahajan R,Rai B,et al.Toxicity and clinical outcomes with definitive three-dimensional conformal radiotherapy(3DCRT)and concurrent cisplatin chemotherapy in locally advanced cervical carcinoma[J].Jpn J Clin Oncol,2019,49(2):146-152. [4]李晔雄.肿瘤放射治疗学[M].第5版.北京:中国协和医科大学出版社,2018:1788-1868. [5]Wang Q,Ye T,Chen HL,et al.Correlation between intensity modulated radiotherapy and bone marrow suppression breast cancer[J].Eur Rev Med Pharmacol Sci,2016,20(1):75-81. [6]陈宏博,余增荣,丁小凡,等.盆腔肿瘤IMRT下骨髓剂量-体积参数与急性血液学毒性相关性研究[J].实用肿瘤学杂志,2019,33(4):361-366. [7]Li N,Liu X,Zhai F,et al.Association between dose-volume parameters and acute bone marrow suppression in rectal cancer patients treated with concurrent chemoradiotherapy[J].Oncotarget,2017,8(54):92904-92913. [8]Klopp AH,Yeung AR,Deshmukh S,et al.Patient-Reported Toxicity During Pelvic Intensity-Modulated Radiation Therapy:NRG Oncology-RTOG 1203[J].J Clin Oncol,2018,36(24):2538-2544. [9]唐滟,袁亚维.调强放疗同步化疗治疗宫颈癌血液学毒性相关因素分析[J].肿瘤防治研究,2016,43(4):277-281. [10]温列东,黄维,伍万春,等.宫颈癌骨髓限量调强放疗对急性骨髓抑制的影响[J].中国医学物理学杂志,2018,35(4):399-403. [11]Robinson M,Muirhead R,Jacobs C,et al.Response of FDG avid pelvic bone marrow to concurrent chemoradiation for anal cancer[J].Radiother Oncol,2020(143):19-23. [12]Newman NB,Sidhu MK,Baby R,et al.Long-Term Bone Marrow Suppression During Postoperative Chemotherapy in Rectal Cancer Patients After Preoperative Chemoradiation Therapy[J].Int J Radiat Oncol Biol Phys,2016,94(5):1052-1060. [13]Wong GL,Wbng VW,Chan Y,et al.High incidence of mortality and recurrent bleeding in patients with Helicobacter pylori-negative idiopathic bleeding ulcers[J].Gastroenterology,2009,37(2):525-531. [14]Huang XE,Cao J,Qian ZY,et al.Leucogen tablets at 60 mg three times per day are safe and effective to control febrile neutropenia[J].Asian Pac J Cancer Prev,2014,15(19):8495-8497. [15]杨春华,王侠,章龙珍,等.中晚期宫颈癌同步推量调强放疗的临床研究[J].国际肿瘤学杂志,2018,45(9):544-547. [16]潘文斌.利可君防治恶性肿瘤放疗所致骨髓抑制的效果评估[J].中华肿瘤防治杂志,2016,23(S1):228-229.

更新日期/Last Update: 1900-01-01